Is Danggui safe to be taken by breast cancer patients? - A skepticism finally answered by comprehensive preclinical evidence
Publication in refereed journal

替代計量分析
.

其它資訊
摘要Angelica sinensis (AS, Danggui) has long been regarded to stimulate breast cancer growth; hence, the use of AS in breast cancer patients remains a major concern for both patients and practitioners. Since safety studies of herbs would be unethical to carry out in patients, the present study aimed to investigate the potential unsafe effects of AS in a systematic pre-clinical approach. Human breast cancer cells, breast orthotopic tumor-bearing mouse models, as well as primary breast cancer cells from patients’ tumors were used to evaluate the effect of AS hot water extract on the progression of breast tumors and/or growth of breast cancer cells. We showed that AS is not that stimulatory in breast cancer both in vitro and in vivo, though AS should still be used with caution in estrogen receptor-positive breast cancer patients. This novel approach of applying breast cancer cell lines, xenograft, and syngeneic tumors models, as well as primary breast cancer cells from patients’ tumors in Chinese medicines safety evaluation was proven feasible. Our finding is important information for patients, Chinese medicine practitioners, and clinicians on the safety use of AS in breast cancer, which will affect future clinical practice.
著者Yue GGL, Wong LS, Leung HW, Gao S, Tsang JYS, Lin ZX, Law BKB, Tse GMK, Lau CBS
期刊名稱Frontiers in Pharmacology
出版年份2019
月份6
日期25
卷號10
出版社FRONTIERS MEDIA SA
文章號碼706
國際標準期刊號1663-9812
語言英式英語
關鍵詞breast cancer, Angelica sinensis, safety, estrogenic herbs, primary breast cancer cells, Chinese herbal medicines
Web of Science 學科類別Pharmacology & Pharmacy;Pharmacology & Pharmacy

上次更新時間 2021-10-06 於 23:59